title: [Clinical trial on ibandronate in patients with tumor-associated hypercalcemia].
abstract: OBJECTIVE
  Ibandronate, a third generation bisphosphonate, inhibits bone resorption in human and animal studies. This study is to evaluate the efficacy and safety of ibandronate as a single agent in patients with tumor-associated hypercalcemia.
  
  
  METHODS
  An open, multicenter, non-controlled clinical trial was conducted in 22 patients. The patients received 2 mg ibandronate intravenously if the corrected calcium was less than 3.0 mmol/L but more than 2.7 mmol/L; they received 4 mg ibandronate iv if corrected calcium was more than 3.0 mmol/L.
  
  
  RESULTS
  There was 100% efficacy in these two dose groups but the calcium correcting effect was more pronounced in the 4-mg dose group than the 2-mg dose group. The most common adverse reactions were fever and skin itching with an incidence of 4.5%.
  
  
  CONCLUSIONS
  Ibandronate is active in patients with tumor-associated hypercalcemia and the adverse effects are well tolerated.
authors.affiliation: Department of Breast Cancer, Hospital Affiliated to Academy of Military Medical Sciences, Beijing 100039, China.
authors.forename: Tao
authors.initials: T
authors.lastname: Wang
authors.forename: San-tai
authors.initials: ST
authors.lastname: Song
authors.forename: Ze-fei
authors.initials: ZF
authors.lastname: Jiang
authors.forename: Shou-geng
authors.initials: SG
authors.lastname: Bian
authors.forename: Ya-jie
authors.initials: YJ
authors.lastname: Wang
authors.forename: Li-qing
authors.initials: LQ
authors.lastname: Li
authors.forename: Jun
authors.initials: J
authors.lastname: Zhu
mesh_terms: D001859:Bone Neoplasms / Q000150:complications / Q000378:metabolism; D001943:Breast Neoplasms / Q000150:complications* / Q000473:pathology; D002118:Calcium / Q000097:blood*; D004164:Diphosphonates / Q000008:administration & dosage / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D005334:Fever / Q000139:chemically induced; D006801:Humans; D006934:Hypercalcemia / Q000097:blood / Q000188:drug therapy* / Q000209:etiology; D000077557:Ibandronic Acid; D008175:Lung Neoplasms / Q000150:complications* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000150:complications; D010758:Phosphorus / Q000097:blood; D011537:Pruritus / Q000139:chemically induced
chemical_list: D004164:Diphosphonates; D010758:Phosphorus; D002118:Calcium; D000077557:Ibandronic Acid